Interview: Dr. Amr Morsy – CEO, Rameda, Egypt
Five days before the January 25th revolution of 2011, Rameda changed ownership and CEO Amr Morsy set out to turn-around the mismanaged business. Five years later, revenues are up 4.5…
MINAPHARM ranks among the leading pharmaceutical companies in Egypt and the Middle East. The company maintains one of the broadest quality-products portfolio within the industry. Their longstanding expertise covers a broad spectrum of medicines, ranging from small molecules to extremely complex bioengineered proteins. Minapharm is leading a transition towards high-value biologicals in developing markets, while expanding a robust small-molecule setup in a business model that represents a far departure from existing regional models. In addition to production of life-saving and life-enhancing medicines, MINAPHARM is adopting an international operation platform for biotechnology and cellular engineering. Novel scientific solutions and technologies contribute to the development of products that were unimaginable a decade ago. Scientific excellence and expertise in cellular and bioprocess engineering enable the companies mission to provide not only developed markets, but also emerging markets with significant economic molecules, thus striking the next frontier. MINAPHARM is constantly demonstrating its ability to achieve the balance between Innovation and Affordability, hence, facing the most complex challenges of unmet medical needs in emerging countries.
Contact
El-Bardissi St., 2T Takseem Asmaa Fahmy St., Heliopolis, Cairo – Egypt.
(+202) 2414-3170/1/2/3/4/5
(+202) 2414-3179
Five days before the January 25th revolution of 2011, Rameda changed ownership and CEO Amr Morsy set out to turn-around the mismanaged business. Five years later, revenues are up 4.5…
Tabuk Pharmaceuticals, the largest private Saudi pharmaceutical company with commercial operations in 25 countries in middle east and 5 European countries with a portfolio of more than 250 products, chose…
Egypt can boast some of the most modern manufacturing sites in the Arab world. The CEO of Future Pharmaceutical Industries discusses the importance of promoting exports, the ambitious plans of…
Starting as a pharmacy chain, Hefny Pharma Group has developed into a group focused on manufacturing, importing and distributing pharmaceutical products to the Egyptian market, with an eye on the…
The chairman of Egypt’s largest holding company for pharmaceutical manufacturers, ACDIMA, shares his vision for how Egyptian manufacturers can enhance their competitiveness in the coming years, and extend their activities…
Marcyrl grew 40 percent and jumped from 15th to 9th place in the Egyptian market in 2014. With growth remaining strong, the board explains the keys to success for doing…
With a large and growing population, and significant domestic health needs, Lilly Egypt general manager Ozkan Ozdogan sees many opportunities for various stakeholders to serve patients, and is focusing on…
Servier Egypt’s recently arrived general manager shares his first impressions and assessments of the Egyptian business environment, and discusses the potential he sees for Servier Egypt to build upon its…
OrganoPharma’s founder and chairman Dr. Mowfak Sakr explains how he founded his company to try and provide the 40 million people in Egypt who lack healthcare insurance of any kind…
Phyto-Pharmaceuticals often offer better, more sustainable treatment solutions than synthetic pharmaceuticals, explains the Sekem group’s CEO Helmy Abouleish. Atos Pharma’s CEO Ashraf Mamdouh expands on the companies current plans for…
Medical Union Pharmaceuticals (MUP) acquired Lilly’s Egyptian human insulin vial manufacturing facility in early 2015. Managing Director Ahmed Kelani discusses the national significance of this acquisition given Egypt’s high prevalence…
As the founder of Egypt’s leading commercial agent for advanced medical technologies, Mahmoud Bagneid has a simple goal for Egyptian healthcare; for all Egyptian’s to be aware that they should…
See our Cookie Privacy Policy Here